Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer
August 23rd 2021Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.
Read More
Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer
August 7th 2016Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.
Read More
Dr. Shore on Lack of Reported Symptoms in Men With Prostate Cancer
August 10th 2015Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.
Read More